Edwards Lifesciences Corp: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on Apr 28, 2021 and accepted by EDGAR at Apr 28, 2021, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $1.22bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $293.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $923.2m | us-gaap:GrossProfit |
| Research and development | 3 months2021-01-01 to 2021-03-31 | $207.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-01-01 to 2021-03-31 | $330.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | $383.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-01-01 to 2021-03-31 | $51.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-03-31 | $338.2m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | $0.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | $0.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-03-31 | 631,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | $300.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2021-01-01 to 2021-03-31 | $106.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2021-01-01 to 2021-03-31 | $302.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-03-31 | $1.17bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $3.07bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $7.21bn | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $799.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2021-03-31 | $595.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2021-03-31 | $4.66bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001099800-21-000012. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.